- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- scAAV9.U7.ACCA
- Biological
- Lead sponsor
- Megan Waldrop
- Other
- Eligibility
- 6 Months to 13 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Condition Directory
Duchenne Muscular Dystrophy clinical trials
Directory of U.S. ClinicalTrials.gov public records for Duchenne Muscular Dystrophy. Browse Duchenne Muscular Dystrophy recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 24, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
237
Shown on this page
12
Current sort
Recently updated
Condition scope
Duchenne Muscular Dystrophy
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Duchenne Muscular Dystrophy studies are organized in the registry
Duchenne records are often titled with just “Duchenne” or the abbreviation DMD, and much of the portfolio is organized around a therapeutic platform — gene transfer, exon skipping — which appears in titles. Because Duchenne is diagnosed in childhood, the age filter meaningfully changes what you see.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 73–84 of 237 matching trials for Duchenne Muscular Dystrophy.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Eteplirsen, Golodirsen, Casimersen
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2033
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 17 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- delandistrogene moxeparvovec, Plasmapheresis
- Genetic · Procedure
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 8 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • St Louis, Missouri • Columbus, Ohio
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- No intervention
- Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Duchenne Muscular Dystrophy, Exon 44
- Interventions
- AOC 1044, Placebo
- Drug
- Lead sponsor
- Avidity Biosciences, Inc.
- Industry
- Eligibility
- 7 Years to 55 Years · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 7 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- delandistrogene moxeparvovec, placebo
- Genetic
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more
- Conditions
- Becker Muscular Dystrophy
- Interventions
- Sevasemten
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
- Interventions
- CAP-1002, Placebo
- Biological · Drug
- Lead sponsor
- Capricor Inc.
- Industry
- Eligibility
- 10 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Sacramento, California • Aurora, Colorado • Orlando, Florida + 6 more
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Not listed
- Lead sponsor
- Red Nucleus Enterprise Solutions, LLC
- Industry
- Eligibility
- 10 Years and older · Male only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Yardley, Pennsylvania
- Conditions
- Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Interventions
- Hyperpolarized 13C-Pyruvate
- Diagnostic Test
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Remote Administration of NSAA
- Other
- Lead sponsor
- Red Nucleus Enterprise Solutions, LLC
- Industry
- Eligibility
- 4 Years to 12 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Malvern, Pennsylvania
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- rAAVrh74.MCK.GALGT2
- Biological
- Lead sponsor
- Kevin Flanigan
- Other
- Eligibility
- 4 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
About this Duchenne Muscular Dystrophy clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Duchenne Muscular Dystrophy as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Duchenne Muscular Dystrophy.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Duchenne Muscular Dystrophy.